<DOC>
	<DOCNO>NCT02580071</DOCNO>
	<brief_summary>The treatment option high-risk acute leukemia patient limited patient often opt hematopoietic stem cell transplant ( HSCT ) . However study show prognosis follow last-resort therapy bleak . At time , less 70 % post-HSCT relapse AML ALL patient even achieve complete remission ; median overall survival cohort might reach one year ; 3-year post-HSCT survival rate might less 20 % . The investigator plan recruit acute leukemia patient CMUH plan receive HSCT , follow rate quality immune reconstitution . As intervention , part patient receive Chinese medicine herbal formula , take 6 months.Differences 1-year post-HSCT condition patient examine .</brief_summary>
	<brief_title>Chinese Herbal Medicine Immune Reconstitution Following HSCT Acute Leukemia Patients</brief_title>
	<detailed_description>We hope enroll 50 high-risk acute leukemia patient receive HSCT China Medical University Hospital . Thereupon , patient consecutively recruit treatment group ( 25 patient ) prescribe Sheng Yu Tang ( 聖愈湯 , SYT ) 2 month follow HSCT , period 6 month , conjunction standard-care treatment . We predict patient interested take SYT , patient interested enter treatment group offer join control group ( 25 patient ) receive standard-care treatment . Since HSCT patient go routine blood examination , study request extract 20ml peripheral blood month additional 20ml bone marrow begin HSCT follow routine aspiration ( est . :0 , +3 , +6 , +9 , +12 month ) . Both treatment control group require contribute peripheral blood bone marrow sample.Blood sample collect patient reach 1-year post-HSCT , flow cytometry use examine difference immune reconstitution rate two group . As secondary outcome measurement , study make use minimal residual disease ( MRD ) measure , frequency opportunistic infection , hospitalization result routine check-up record patient history .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Discharged hospital . Diagnosed ALL , AML MDSAML . Received allogeneic haploidentical peripheral blood HSCT . Willing supply blood sample analysis . Willing comply study intervention followups . unable , due know allergy reason , orally take Chinese Herbal Medicine .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>Chinese Herbal Medicine</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>clinical trial</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
</DOC>